Related Experiment Video
Updated: Feb 22, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Cold Atmospheric Plasma in the Treatment of Osteosarcoma
Denis Gümbel1,2, Sander Bekeschus3, Nadine Gelbrich4
1Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany. denis.guembel@uni-greifswald.de.
Abstract:
Human osteosarcoma (OS) is the most common primary malignant bone tumor occurring most commonly in adolescents and young adults. Major improvements in disease-free survival have been achieved by implementing a combination therapy consisting of radical surgical resection of the tumor and systemic multi-agent chemotherapy. However, long-term survival remains poor, so novel targeted therapies to improve outcomes for patients with osteosarcoma remains an area of active research. This includes immunotherapy, photodynamic therapy, or treatment with nanoparticles. Cold atmospheric plasma (CAP), a highly reactive (partially) ionized physical state, has been shown to inherit a significant anticancer capacity, leading to a new field in medicine called "plasma oncology." The current article summarizes the potential of CAP in the treatment of human OS and reviews the underlying molecular mode of action.
Insights
Cold atmospheric plasma (CAP) shows promise for treating human osteosarcoma (OS), a rare bone cancer. This review explores CAP
Area of Science:
- Oncology
- Biophysics
- Materials Science
Background:
- Osteosarcoma (OS) is the most common primary malignant bone tumor, particularly in adolescents and young adults.
- Current treatments combining surgery and chemotherapy have improved survival, but long-term outcomes remain poor.
- Novel targeted therapies, including immunotherapy and nanoparticle-based treatments, are under active investigation for OS.
Purpose of the Study:
- To summarize the potential of cold atmospheric plasma (CAP) in treating human osteosarcoma (OS).
- To review the underlying molecular mechanisms of CAP's anticancer effects in OS.
- To highlight CAP as a promising novel therapeutic approach in plasma oncology.
Main Methods:
- Review of existing literature on cold atmospheric plasma (CAP) applications in cancer therapy.
- Analysis of studies investigating CAP's effects on human osteosarcoma (OS) cell lines and models.
- Examination of the molecular pathways and mechanisms targeted by CAP.
Main Results:
- Cold atmospheric plasma (CAP) exhibits significant anticancer capacity against human osteosarcoma.
- CAP treatment can induce apoptosis and inhibit proliferation in OS cells through various molecular pathways.
- The review consolidates evidence supporting CAP's potential as a targeted therapy for OS.
Conclusions:
- Cold atmospheric plasma (CAP) presents a promising novel therapeutic strategy for osteosarcoma (OS).
- Further research into CAP's molecular mechanisms could lead to innovative clinical applications in plasma oncology.
- CAP offers a potential new avenue to improve outcomes for patients with this challenging bone cancer.
